Displaying 41 - 60 of 212
Download
PIPS Search Results
PIP Number Active Substance Conditions / Indications Invented Name Therapeutic area Decision Type Compliance Check Compliance outcome Date Published
MHRA-101426-PIP01-24
  • Deutetrabenazine
  • Treatment of tardive dyskinesia
  • Austedo
  • Austedo
  • Austedo
  • Austedo
  • Austedo
  • Austedo
  • Austedo
  • Austedo
  • Austedo
  • Austedo
  • Austedo
  • Neurology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101129-PIP01-23
  • Domvanalimab
  • Treatment of lung cancer
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101128-PIP01-23
  • Domvanalimab
  • Treatment of gastric and gastroesophageal junction adenocarcinoma. Treatment of oesophageal carcinoma.
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101441-PIP01-24
  • modified recombinant version of the human myeloid-derived growth factor
  • Treatment of ischaemic coronary artery disorders
  • Not available at present
  • Cardiovascular Diseases
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101493-PIP01-24
  • anti-alpha-synuclein recombinant humanised monoclonal antibody (Company code UCB7853)
  • Treatment of Parkinson's disease
  • Neurology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101630-PIP01-24-M01 (update)
  • LISOCABTAGENE MARALEUCEL
  • Treatment of B-lymphoblastic leukaemia/lymphoma
  • Treatment of mature B-cell neoplasm
  • Breyanzi
  • Breyanzi
  • Breyanzi
  • Breyanzi
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101520-PIP01-24-M01 (update)
  • ECULIZUMAB
  • Treatment of neuromyelitis optica spectrum disorders.
  • SOLIRIS
  • SOLIRIS
  • Neurology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101496-PIP01-24
  • zirconium (89Zr) girentuximab senvedoxam
  • Diagnostic evaluation of indeterminate renal masses detected by conventional imaging
  • Not available at present
  • Uro-Nephrology
  • Diagnostic
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101395-PIP01-24
  • Zanidatamab
  • Treatment of biliary tract cancer (BTC).
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101410-PIP01-24
  • ISATUXIMAB
  • Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue
  • Sarclisa
  • Sarclisa
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101334-PIP01-24
  • Insulin Efsitora Alfa (LY3209590)
  • Treatment of type 1 diabetes mellitus
  • Treatment of type 2 diabetes mellitus
  • Endocrinology-Gynaecology-Fertility-metabolism
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101333-PIP01-24
  • 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone monohydrate
  • Treatment of Parkinson's disease
  • Neurology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101170-PIP01-23
  • IRINOTECAN HYDROCHLORIDE TRIHYDRATE
  • Treatment of pancreatic cancer
  • ONIVYDE pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion
  • ONIVYDE pegylated liposomal
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101132-PIP01-23
  • Vepdegestrant
  • Treatment breast malignant neoplasms
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101468-PIP01-24
  • DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE
  • baxdrostat
  • Treatment of Chronic Kidney Disease
  • Uro-Nephrology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101431-PIP01-24
  • SODIUM PHENYLBUTYRATE
  • Ursodoxicoltaurine
  • Treatment of progressive supranuclear palsy
  • Relyvrio
  • Albrioza
  • Neurology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101326-PIP01-24
  • Human IgG4 monoclonal antibody against BCMA and CD3
  • Treatment of multiple myeloma
  • Not available at present
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101338-PIP01-24
  • elinzanetant
  • Treatment of vasomotor symptoms caused by endocrine therapy related to breast cancer
  • Endocrinology-Gynaecology-Fertility-metabolism
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101186-PIP01-23
  • FARICIMAB
  • Treatment of choroidal neovascularisation secondary to pathologic myopia
  • Vabysmo
  • Vabysmo
  • Ophthamology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101288-PIP01-23
  • Interleukin-2
  • Interleukin-1 beta, human
  • Granulocyte colony-stimulating factor
  • Tumor necrosis factor-alpha
  • Interferon gamma
  • Treatment of squamous cell carcinoma of the head and neck (SCCHN)
  • Multikine
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
Download XLSX